JK Lakshmi Cement shares will be in focus after the company received a Rs 45.6 crore tax demand for AY 2022-23. The firm disclosed that the assessment order was received on March 18, 2025. The company plans to appeal the order, stating that the demand is legally untenable and unlikely to impact its operations.Read More

Axis Securities recommends buying Sarda Energy & Minerals stock with a target price of Rs 615, highlighting a recent breakout from consolidation, supported by technical indicators. For Q3 2024, the company reported a consolidated total income of Rs 1318.74 crore, up 8.61% from the previous quarter, along with a strong net profit of Rs 188.16...Read More

Indian benchmark indices, Sensex and Nifty, continued their rebound for the third consecutive session on Wednesday, led by gains in metal and financial stocks. However, caution ahead of the U.S. Federal Reserve’s policy decision could cap further gains.Read More

Startups, which are eyeing public listing, are increasingly opting for confidential filing route amid choppy and unpredictable markets that have nudged several new age companies to reassess and go slow on their IPO plans.Read More

In this overall, uncertain global environment, India seems better placed. Currently, we are out of the cross hairs from the tariff perspective but need to watch what happens in April, when reciprocal tariff policies are implemented.Read More

As Q4 2025 unfolds, Indian equity markets are recovering from earlier downturns. Historical patterns suggest a pre-earnings rally, slight correction during results, and potential post-earnings rebound. Experts believe that market recovery hinges on corporate earnings and external factors, predicting an optimistic outlook if earnings improve.Read More

Super Iron Foundry’s shares will debut on the BSE SME platform at a slight premium over the IPO price of Rs 108. The company raised Rs 68 crore, which will fund working capital and debt repayment. It exports to Europe and the Middle East and has a 72,000 MT annual production capacity in West Bengal,...Read More

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.Read More

Gold prices continue to rise as investors treat gold as an investment. Central banks are accumulating gold. Geopolitical risks and inflation concerns drive demand. Analysts predict that gold may reach Rs 1 lakh per 10 grams in the long-term. They recommend a systematic investment approach for investors to benefit from corrections.Read More

As long as the stock is priced above the 200-day SMA on the daily time frame, it is generally considered to be an overall uptrend.Read More